Cell therapy is emerging as a very promising therapeutic modality against cancer,
spearheaded by the clinical success of chimeric antigen receptor (CAR) modified T cells for …

The discovery of human pluripotent stem cells (PSCs) at the turn of the century opened the
door to a new generation of regenerative medicine research. Among PSCs, the donors …

Human induced pluripotent stem cells (iPSCs) can be limitlessly expanded and
differentiated into almost all cell types. Moreover, they are amenable to gene manipulation …

Cell therapy is usually defined as the treatment or prevention of human disease by
supplementation with cells that have been selected, manipulated, and pharmacologically …

Adoptive cell therapy (ACT) using chimeric antigen receptor (CAR) T cells holds impressive
clinical outcomes especially in patients who are refractory to other kinds of therapy …

T cells, natural killer (NK) cells, macrophages (Macs), and dendritic cells (DCs) are among
the most common sources for immune-cell-based therapies for cancer. Antitumor activity can …

Induced pluripotent stem cells (iPSCs) were first described in 2006 and have since emerged
as a promising cell source for clinical applications. The rapid progression in iPSC …

Derivation of human embryonic stem cell (hES) lines in 1998 was not only a major
technological breakthrough in the field of regenerative medicine; it also triggered a …

Successfully reprogramming somatic cells to a pluripotent state generates induced
pluripotent stem (iPS) cells (or iPSCs), which have extensive self-renewal capacity like …

Generation of induced pluripotent stem cells (iPSCs) has revolutionized the field of
regenerative medicine by providing researchers with a unique tool to derive disease-specific …